From: Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
 | GLP-1 | References | GLP-1R agonist | References |
---|---|---|---|---|
 | Decreases gastrointestinal motility extending the entry of nutrients to be absorbed by the GIT | [18] | mRNA transcripts were demonstrated in the human heart. | [31] |
 | Normalizes postprandial glucose elevations by decreasing TGI motility, which seems to be more important than its insulinotropic effects. | [19] | Induces a mean increase in HR in patients with T2D. | [77] |
 | Improves endothelial function expressed by an increase in flow-mediated vasodilation of the brachial artery, independent of changes in systolic and diastolic blood pressure during a hyperinsulinemic clamp in patients with T2D with stable CAD. | [36] | Increases endothelial nitric oxide synthase phosphorylation and nitric oxide production by the AMPK-dependent pathway in cultured Human Coronary Artery Endothelial Cells. | |
 | Increases myocardial glucose uptake under basal conditions in lean humans, but this effect was impaired in T2D. | [47] | With metformin ameliorates high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. | [59] |
 | improves global and regional LV wall motion scores reducing stay and in-hospital mortality of patients with LV dysfunction after myocardial infarction. | Increases endogenous antioxidant defenses, inhibits of cardiomyocyte apoptosis, attenuates of endothelial inflammation and dysfunction. | [62] | |
 | Protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. | [58] | Reduces in 19% the incidence of major adverse cardiovascular and cerebrovascular events (MACCE) and in 12% cardiovascular hospitalizations. | [71] |
 | Enhances acetylcholine-induced forearm blood flow. | [61] | Reduces pulmonary capillary wedge pressure and increased both inotropism and chronotropism. In T2D patients with chronic heart failure. | [73] |
Human studies | Increases muscle sympathetic nerve activity without affecting BP, norepinephrine plasma concentration, or the sympathetic/parasympathetic balance, where sympathetic drive is at least partially compensated by an increase in the parasympathetic activity | [62] | Reductes infarct size and improves subclinical LV function when added to primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction. | [14] |
 | May have renoprotective function by significantly increased excretion of sodium, calcium, and chloride and significantly decreased excretion of H + in obese patient. | [63] | When administered once in a week assistes more patients in reaching the majority of ADA-recommended therapeutic goals than treatment with sitagliptin, pioglitazone, or insulin glargine as shown by clinical trials. |  |
 | Concentration in human plasma is found to be positively associated with total coronary plaque load. | [66] | When administered once in a week elicites a greater response than does short-acting exenatide once a day, improving glycemic and lipids controls, lipoprotein metabolism, and decreasing systemic inflammation. |  |
 | Improves LVEF, myocardial ventilation oxygen consumption, 6-min walk distance, and quality of life. In both diabetic and non-diabetic patients presenting class II/IV heart failure | [78] |  |  |
 | Achieves better glycemic control and comparable hemodynamic recovery without the requirements for high-dose insulin or inotropes when infused perioperatively in patients with CAD and preserved LV function scheduled to undergo coronary artery bypass grafting. There were also more frequent arrhythmias requiring anti-arrhythmic agents in the control group. | [79] |  |  |
 | Treatment is safe and elicites a significant improvement LVEF in patients with acute MI and LVEF <40% after successful primary angioplasty when compared with control. | [74] |  |  |
 | Protects the heart from ischemic LV dysfunction induced by dobutamine stress in patients with CAD. | [75] |  |  |